Ipsen at a glance

Innovation for

patient care

Press releases

17 July 2014

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic…

11 July 2014

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe

YOU ARE ON IPSEN'S CORPORATE WEBSITE

The corporate website is governed by the International Federation of Pharmaceutical Manufacturers & Associations code of practice.
Certain information provided on this website may not be strictly in conformity with the French regulations on advertising.

> Close